Literature DB >> 11831690

Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d.

J C Kim1, R A Spence, P F Currier, X Lu, M R Denison.   

Abstract

Mouse hepatitis virus strain A59 (MHV-A59) encodes within the 22-kb gene 1 a large polyprotein containing three proteinase domains with proven or predicted cysteine catalytic residues. E64d, a specific, irreversible inhibitor of cysteine (thiol) proteinases, inhibits the processing of the gene 1 polyprotein. Specifically, E64d blocks the carboxy-terminal cleavage of p65. E64d also inhibits replication of MHV-A59 in murine DBT cells in a dose-dependent manner, resulting in reduced virus titers and viral syncytia formation. This inhibition of replication is associated with a rapid shutoff of new viral RNA synthesis, in a manner similar to that seen in the presence of cycloheximide. The E64d-associated inhibition of RNA synthesis likely results from E64d-specific inhibition of processing of the gene 1 polyprotein, resulting in inactive proteinase or replicase proteins. These results indicate that processing of the MHV-A59 gene 1-encoded polyprotein is required throughout infection to sustain RNA synthesis and virus replication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 11831690      PMCID: PMC7131484          DOI: 10.1006/viro.1995.1123

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  63 in total

1.  Identification of mouse hepatitis virus papain-like proteinase 2 activity.

Authors:  A Kanjanahaluethai; S C Baker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Replication of murine hepatitis virus is regulated by papain-like proteinase 1 processing of nonstructural proteins 1, 2, and 3.

Authors:  Rachel L Graham; Mark R Denison
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papain-like protease?

Authors:  Traian Sulea; Holger A Lindner; Enrico O Purisima; Robert Ménard
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Mouse hepatitis virus replicase proteins associate with two distinct populations of intracellular membranes.

Authors:  A C Sims; J Ostermann; M R Denison
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity.

Authors:  Naina Barretto; Dalia Jukneliene; Kiira Ratia; Zhongbin Chen; Andrew D Mesecar; Susan C Baker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Characterization of the rubella virus nonstructural protease domain and its cleavage site.

Authors:  J P Chen; J H Strauss; E G Strauss; T K Frey
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry.

Authors:  Zhaozhu Qiu; Susan T Hingley; Graham Simmons; Christopher Yu; Jayasri Das Sarma; Paul Bates; Susan R Weiss
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Functional and genetic studies of the substrate specificity of coronavirus infectious bronchitis virus 3C-like proteinase.

Authors:  Shouguo Fang; Hongyuan Shen; Jibin Wang; Felicia P L Tay; Ding Xiang Liu
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

9.  Characterization of the expression, intracellular localization, and replication complex association of the putative mouse hepatitis virus RNA-dependent RNA polymerase.

Authors:  Sarah M Brockway; Corrie T Clay; Xiao Tao Lu; Mark R Denison
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  A novel mutation in murine hepatitis virus nsp5, the viral 3C-like proteinase, causes temperature-sensitive defects in viral growth and protein processing.

Authors:  Jennifer S Sparks; Eric F Donaldson; Xiaotao Lu; Ralph S Baric; Mark R Denison
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.